- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07665203
Home Air Pollution in Children With Cystic Fibrosis Study (HEROIC-CF)
17. juni 2026 opdateret af: Meghan McGarry, Seattle Children's Hospital
Cystic Fibrosis (CF) is a devastating chronic pulmonary disease that continues to cause significant morbidity and mortality despite great advances in therapies.
Hispanic children with CF have worse outcomes, including higher mortality and more severe pulmonary disease, than non-Hispanic white children with CF.
It is not known why Hispanic children with CF have more severe disease as it is not explained by CFTR genetic severity, diagnosis age, or socioeconomic status.
The health disparities have worsened, not improved, for Hispanic children with CF since the development of new disease-altering therapeutics, CFTR modulators.
It is critical to determine what is contributing to lung disease severity in Hispanic children with CF.
Non-genetic factors, including environmental exposures, are estimated to account for 50% of lung disease severity variability in CF.
Air pollution exposure during early childhood is associated with lower pulmonary function in healthy children and severe lung disease in children with asthma.
However, air pollution exposure is vastly understudied in other chronic pulmonary diseases of childhood, such as CF.
Investigating air pollution exposure in CF may provide vital information about the drivers of health disparities in Hispanic children with CF and about the environmental exposures influencing lung disease severity across all children with CF.
To investigate air pollution exposure in children with CF, the investigators have assembled a multidisciplinary team of international experts in air pollution exposure, CF lung disease, health disparities, and pulmonary microbiome.
The investigators will use two phenomenally rich databases, the CF Foundation Patient Registry and the University of Washington Spatiotemporal Air Pollution Exposure Model, to investigate the first aim: 1A) To determine whether neighborhood-level ambient air pollution exposure during childhood differs between 1500 Hispanic and 8500 non-Hispanic white cwCF in the CF Foundation Patient Registry, and 1B) To determine if neighborhood-level ambient air pollution exposure is associated with lung disease severity in Hispanic and non-Hispanic white cwCF.
Across six geographically diverse clinical research CF centers, the investigators will enroll 100 Hispanic and 100 non-Hispanic children with CF to investigate the following aims: 2) To assess differences in residential indoor and ambient air pollution exposures by ethnicity in 200 cwCF, as well as the association between such exposure and pulmonary function by ethnicity, 3) To investigate the association of indoor and ambient air pollution exposure on airway inflammation and microbiome diversity and composition in Hispanic and non-Hispanic white cwCF using metatranscriptomic RNA sequencing.
The HEROIC-CF Study is poised to advance the knowledge of the effect of air pollution exposure on not only CF lung disease severity, but may be a model to understand environmental exposures on disease severity in other chronic pulmonary diseases of childhood.
Studieoversigt
Status
Ikke rekrutterer endnu
Betingelser
Undersøgelsestype
Observationel
Tilmelding (Anslået)
200
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
- Barn
- Voksen
Tager imod sunde frivillige
Ingen
Prøveudtagningsmetode
Ikke-sandsynlighedsprøve
Studiebefolkning
Children with confirmed cystic fibrosis
Beskrivelse
Inclusion Criteria:
- Age 6 to 18 years old
- Hispanic of any race or non-Hispanic white
- Diagnosed with cystic fibrosis
Exclusion Criteria:
- Cannot perform spirometry
- Planning to move in next 12 months
- Spends <4 nights a week in one residence
- Active smoking in the home
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Indoor Air Pollution
Tidsramme: 12 Months
|
Measurement of PM2.5 indoors via PurpleAir monitors
|
12 Months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Pulmonary Function
Tidsramme: 12 months
|
Pulmonary Function Test (PFT) using spirometry: FVC, FEV1, FEV1/FVC, and FEF25%-75%
|
12 months
|
|
Airway inflammation
Tidsramme: 12 months
|
Airway inflammation will be measured using sequencing of oropharyngeal swabs
|
12 months
|
|
Airway microbiome
Tidsramme: 12 months
|
Airway microbiome will be measured using sequencing of oropharyngeal swabs
|
12 months
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Samarbejdspartnere
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Anslået)
1. september 2026
Primær færdiggørelse (Anslået)
30. april 2031
Studieafslutning (Anslået)
30. april 2031
Datoer for studieregistrering
Først indsendt
12. juni 2026
Først indsendt, der opfyldte QC-kriterier
17. juni 2026
Først opslået (Faktiske)
24. juni 2026
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
24. juni 2026
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
17. juni 2026
Sidst verificeret
1. juni 2026
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- STUDY00005521
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
UBESLUTET
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Ingen
Studerer et amerikansk FDA-reguleret enhedsprodukt
Ingen
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Cystisk fibrose (CF)
-
Medical Center AlkmaarAfsluttetIkke-CF bronkiektasiHolland
-
The Hospital for Sick ChildrenAktiv, ikke rekrutterendeGruppe 1: Sunde kontroller | Gruppe 2: Stabil CF | Gruppe 3: CF-deltagere forventes at modtage CFTR-modulatorterapi | Gruppe 4: 4-8-årige CF-deltagere, der starter Triple Combination Modulator TherapyCanada
-
COPD FoundationRekrutteringIkke-CF bronkiektasi | Ikke-tuberkulose mykobakterier (NTM)Forenede Stater
-
M.D. Anderson Cancer CenterRekrutteringFibrose | Lymfødem | Fibrosis syndrom | Hoved & amp; HalskræftForenede Stater
-
Nicole HamblettCystic Fibrosis FoundationIkke rekrutterer endnu
-
University of NottinghamRekrutteringCystisk fibrose (CF)Det Forenede Kongerige
-
The Hospital for Sick ChildrenIkke rekrutterer endnu
-
Meyer Children's Hospital IRCCSRekruttering
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldRekrutteringCystisk fibrose (CF)Det Forenede Kongerige
-
Ohio State UniversityIkke rekrutterer endnu